Quarterly ResultAug 5, 2026, 04:18 PM
GoodRx Q2 Revenue $200.4M, Net Income $8.5M; EPS $0.02
AI Summary
GoodRx Holdings, Inc. reported a decline in its second quarter and first half 2026 financial results. Q2 revenue decreased to $200.4 million from $203.1 million year-over-year, with net income falling to $8.5 million and diluted EPS to $0.02. For the first six months of 2026, revenue was $394.4 million, down from $406.0 million in the prior year, and net income was $9.7 million. Despite the revenue and net income decline, net cash provided by operating activities increased to $92.7 million for the first half of 2026, and total assets grew significantly to $2.34 billion.
Key Highlights
- Q2 2026 Revenue decreased to $200.4 million from $203.1 million year-over-year.
- Q2 2026 Net Income fell to $8.5 million from $12.8 million year-over-year.
- Q2 2026 Diluted EPS decreased to $0.02 from $0.04 year-over-year.
- H1 2026 Revenue decreased to $394.4 million from $406.0 million year-over-year.
- H1 2026 Net Income fell to $9.7 million from $23.9 million year-over-year.
- Net cash provided by operating activities increased to $92.7 million in H1 2026.
- Total assets increased to $2.34 billion at June 30, 2026, from $1.40 billion at Dec 31, 2025.
- Repurchased $14.5 million of Class A common stock in H1 2026.
Price Impact
More from GDRX